Indeed, in silico methods can assist AD drug discovery in rationally selecting compounds for in vitro screening that present a higher probability of being actives against known targets involved in pathological processes, namely BACE1, that is a relevant therapeutic target for AD. The gene discussed is BACE1; the disease is Alzheimer disease.